Purpose. Human pregnane X receptor (hPXR) has a key role in regulating metabolism of endogenous and exogenous substances. Identification of novel hPXR activators among commercial drugs aids in avoiding drug-drug interactions with future co-administered drugs. Methods. Virtual screening with Structure-Activity Relationship (SAR) models has been applied for identification of novel hPXR activators. Ligand-based modeling was conducted with Discover Studio (DS) 2.1. Bayesian classification models were generated with a training set comprising 177 compound, and were validated with a test set with 145 compounds. The activities of commonly prescribed drugs from SCUT database were predicted with one of the Bayesian models. Cell-based luciferase reporter assay was used for evaluation of chemical-mediated hPXR activation. HepG2 cells were co-transfected with PXR expression vector and CYP2B6-luciferase reporter construct. 0.1% DMSO solution was used as vehicle control while rifampicin as the positive control. The binding mode between an experimental validated hPXR modulators and hPXR were studied by docking a ligand into hPXR binding domain (PDB ID: 1NRL) with programs FlexX and SurFlex. Results. The Bayesian models showed specificity and overall prediction accuracy up to 0.92 and 0.69 for test set compounds. One Bayesian model with specificity of 0.92 was selected to screen the SCUT database and retrieved 113 hits. 17 compounds were chosen for in vitro testing. The luciferase reporter assay confirmed that seven drugs, i.e., fluticasone, nimodipine, nisoldipine, beclomethasone, finasteride, flunisolide, and megestrol were previously unidentified potent or moderate hPXR activators, with 2.7 to 18.5- fold increase in luciferase activity compared to vehicle control. Conclusion. In this study, virtual screening based on SAR models successfully identified seven novel hPXR activators among FDA approved and commonly prescribed drugs. The same approach could be used for identification of activators or inhibitors of other protein targets.